The world of healthcare is rapidly embracing the open innovation model and, by extension, corporate venturing. This trend, which has been developing for a long time, was underlined by open innovation’s best-known thinker, Harvard academic Henry Chesbrough, who told last month’s Nature magazine how open innovation in life sci- ences had initially been treated with scepticism but had now taken more of a hold due to open innovation successes at biotech companies such as Genzyme and Millennium. Research and development (R&D) spending in health- care is still increasing slightly, with more than $70bn spent by the 10 biggest companies in the sector in 2012, accord- ing to news provider Fierce Biotech. Yet smaller companies are taking a growing share of R&D – Fierce Biotech said the 10 largest biotech compa- nies spent $11.8bn on research in 2012, up 15%, while some companies, such as Anglo-Dutch AstraZeneca, US-based Pfizer and Japan-based Astellas, are scaling research back. As R&D levels off, many are turning to corporate venturing. New entrants since 2010 include US-based health- care company Merck’s Global Health Innovation Fund, now $500m in size, US and UK-listed Shire Pharmaceuticals, US-based Baxter International, China-based Wuxi Pharmatech, Germany-based Boehringer Ingelheim and New York-listed Teva Pharmaceutical Industries. Many believe this change in the structure of research, plus wider changes to the US healthcare system under President Barack Obama, make it a very interesting time to be in healthcare venturing. Matt Hermann, manag- ing director at Ascension Health Ventures (AHV), which invests on behalf of numerous Roman Catholic healthcare facilities, including hospital Ascension Health, said: “This is the most exciting time to be part of the healthcare venture business as the strategic impact of what we are doing is so high. We believe our LPs [limited partners – investors] enable us to offer unique insights.” He said entrepreneurs and other venture and private equity firms were appreciative of the strategic value Ascen- sion Health Ventures brought to its portfolio companies.Chris Coburn, outgoing executive director of US-based Cleve- land Clinic Innovations, said: “This is a great time to be a big com- pany with investable resources. The arithmetic in the venture com- munity means large players are able to get relatively better value for investments.” People in the sector welcome the move towards venture. Her- mann said: “I believe hospitals and healthcare systems have in the past underinvested in innovation and AHV helps its limited partners become more aware of additional innovations that reduce costs, improve…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?